Use of cancer-specific yeast-secreted in vivo biotinylated recombinant antibodies for serum biomarker discovery
Authors:
Open Access
- 24 July 2008
- journal article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 6 (1) , 41
Abstract
Strategies to discover circulating protein markers of ovarian cancer are urgently needed. We developed a novel technology that permits us to isolate recombinant antibodies directed against the potential serum biomarkers, to facilitate the further development of affinity reagents necessary to construct diagnostic tests.Keywords
This publication has 46 references indexed in Scilit:
- Use of Yeast-SecretedIn vivoBiotinylated Recombinant Antibodies (Biobodies) in Bead-Based ELISAClinical Cancer Research, 2008
- Use of high density antibody arrays to validate and discover cancer serum biomarkersMolecular Oncology, 2007
- Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discoveryCancer Letters, 2007
- Method for generation of in vivo biotinylated recombinant antibodies by yeast matingJournal of Immunological Methods, 2006
- EMILIN1 represents a major stromal element determining human trophoblast invasion of the uterine wallJournal of Cell Science, 2006
- Computational Proteomics Analysis System (CPAS): An Extensible, Open-Source Analytic System for Evaluating and Publishing Proteomic Data and High Throughput Biological ExperimentsJournal of Proteome Research, 2005
- Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinomaGynecologic Oncology, 2004
- Empirical Statistical Model To Estimate the Accuracy of Peptide Identifications Made by MS/MS and Database SearchAnalytical Chemistry, 2002
- Localisation of phosphatidylethanolamine-binding protein in the brain and other tissues of the ratCell and tissue research, 1999
- Purification and characterization of a basic 23 kDa cytosolic protein from bovine brainBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1984